UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stock Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 98.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,249 shares of the company's stock after selling 1,865,335 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.07% of Ginkgo Bioworks worth $295,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Algert Global LLC bought a new position in Ginkgo Bioworks in the 2nd quarter valued at about $36,000. Wellington Wealth Strategies LLC. bought a new position in shares of Ginkgo Bioworks in the second quarter valued at approximately $41,000. Thoroughbred Financial Services LLC purchased a new position in shares of Ginkgo Bioworks during the second quarter valued at approximately $70,000. Pine Valley Investments Ltd Liability Co boosted its position in shares of Ginkgo Bioworks by 653.7% during the second quarter. Pine Valley Investments Ltd Liability Co now owns 220,607 shares of the company's stock valued at $74,000 after buying an additional 191,336 shares during the last quarter. Finally, North Star Asset Management Inc. grew its holdings in Ginkgo Bioworks by 162.6% during the second quarter. North Star Asset Management Inc. now owns 231,100 shares of the company's stock worth $77,000 after buying an additional 143,100 shares in the last quarter. 78.63% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, TD Cowen lifted their price objective on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a "buy" rating in a report on Friday, September 20th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, Ginkgo Bioworks presently has a consensus rating of "Hold" and an average target price of $4.58.

Ginkgo Bioworks Trading Up 15.3 %

Shares of DNA stock traded up $1.34 during trading on Friday, hitting $10.08. The company's stock had a trading volume of 3,320,731 shares, compared to its average volume of 1,176,131. The company has a market cap of $579.39 million, a P/E ratio of -0.77 and a beta of 1.17. The business's fifty day moving average is $8.56. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.26 and a 52 week high of $74.00.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.